Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics reported that its Chief Medical Officer-Urology, Raj S. Pruthi, MD, purchased 55,000 shares of the Company’s common stock in open market transactions on August 29, 2025. This insider purchase reflects a direct acquisition of additional equity by a senior executive using the public market rather than through company grants or option exercises. The disclosure is provided under Regulation FD as furnished information, meaning it is not treated as filed under certain Exchange Act liability provisions or automatically incorporated into other securities law filings.
Sergio Traversa, CEO and Director of Relmada Therapeutics, Inc. (RLMD), reported open-market purchases totaling 265,976 shares across three days, increasing his beneficial ownership to 1,000,000 shares. The Form 4 shows purchases on 08/26/2025 (80,545 shares at a weighted-average price of $0.62), 08/27/2025 (129,455 shares at $0.67), and 08/28/2025 (55,976 shares at $0.74). The filing explains each line represents aggregated open-market trades executed over price ranges: $0.61–$0.65, $0.65–$0.69, and $0.68–$0.79 respectively. All reported holdings are direct and the form is signed by the reporting person.
Schedule 13G/A filed for Relmada Therapeutics (RLMD) discloses beneficial ownership stakes held by Squadron-related filers. Squadron Master Fund LP reports shared beneficial ownership of 2,914,495 shares representing 8.8% of the outstanding common stock. Squadron Capital Management LLC and William Blank each report shared beneficial ownership of 3,298,500 shares, representing 9.9% of the class. The filing clarifies that Squadron Capital Management serves as adviser to funds that hold these shares and that Mr. Blank may be deemed to have investment and voting discretion, while expressly disclaiming beneficial ownership under Rule 13d-4. The ownership percentages are calculated using an issuer-stated share count of 33,191,622 shares outstanding.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) filed a Form 8-K on 7-Aug-2025 announcing Item 2.02 (Results of Operations) and Item 7.01 (Reg FD).
- The company furnished, but did not file, a press release (Ex. 99.1) containing a corporate update and preliminary, unaudited Q2 2025 results for the period ended 30-Jun-2025.
- A conference call and webcast are scheduled for 7-Aug-2025 at 4:30 PM EDT to discuss the update.
- Full unaudited financial statements will appear in the forthcoming Form 10-Q.
- An updated corporate presentation (Ex. 99.2) was also furnished.
- No quantitative financial metrics, guidance, or transactional details are included in the 8-K itself; all figures reside in the referenced exhibits.
The furnished information is not deemed “filed” under the Exchange Act and therefore carries reduced liability. Investors must consult Exhibits 99.1 and 99.2 or the upcoming 10-Q for substantive financial data.
Relmada Therapeutics (RLMD) Q2-25 10-Q snapshot: The company remains pre-revenue and reported a Q2 net loss of $9.9 m (-44% YoY) and a 6-month loss of $27.4 m (-31% YoY) after sharply reducing R&D spend following the wind-down of its REL-1017 and psilocybin programs. Operating expenses fell 46% YoY to $10.2 m for the quarter.
Balance-sheet pressure intensified. Cash & cash equivalents dropped to $1.35 m (vs. $3.86 m YE-24) while short-term investments fell to $19.3 m (vs. $41.1 m), leaving $20.6 m of liquid resources. With $24.5 m operating cash burn in H1 and no revenue, management warns of substantial doubt about going-concern status.
Key corporate actions:
- Acquired Phase-2b-ready Sepranolone for €3 m cash.
- Licensed NDV-01 (Phase 2 NMIBC) for $3.5 m cash plus 3.0 m shares (≈10% dilution) and up to $200 m milestones; early Phase 2 data show 90% 6-month CR.
- Terminated esmethadone and psilocybin programs to focus resources on the new assets.
- Received Nasdaq bid-price deficiency notice; listing transferred to Nasdaq Capital Market with cure period to 19 Jan 2026.
Capital structure: Shares outstanding rose to 33.2 m (vs. 30.2 m YE-24); options outstanding 14.2 m; warrants 0.75 m. No ATM sales to date. Equity now stands at $15.9 m (vs. $35.5 m).
Outlook: Management is evaluating financing alternatives and may scale trial activity; upcoming catalysts include 9- and 12-month NDV-01 Phase 2 read-outs (2H-25) and planned IND for US trials in 1H-26.
Relmada Therapeutics, Inc. (RLMD) – Form 4 insider filing: The company’s Chief Financial Officer, Maged Shenouda, was granted stock options for 600,000 common shares on 06/26/2025. The options carry an exercise price of $0.67 per share and will vest in 16 equal quarterly installments beginning 09/26/2025, fully vesting by 06/26/2035. Following the grant, Shenouda beneficially owns 600,000 derivative securities, reported as direct ownership. No shares were purchased or sold in the open market; this filing records an equity incentive award, aligning executive compensation with future shareholder value.